Focal Laser Ablation As Clinical Treatment of Prostate Cancer: Report from a Delphi Consensus Project

Overview

Journal World J Urol

Specialty Urology

Date 2019 Jan 24

PMID 30671638

Citations 18

Authors

A van Luijtelaar

B M Greenwood

H U Ahmed

A B Barqawi

E Barret

J G R Bomers

M A Brausi

P L Choyke

M R Cooperberg

S Eggener

J F Feller

F Frauscher

A K George

R G Hindley

S F M Jenniskens

L Klotz

G Kovacs

U Lindner

S Loeb

D J Margolis

L S Marks

S May

T D Mcclure

R Montironi

S G Nour

A Oto

T J Polascik

A R Rastinehad

T M De Reyke

J S Reijnen

J J M C H de la Rosette

J P M Sedelaar

D S Sperling

E M Walser

J F Ward

A Villers

S Ghai

J J Futterer

Affiliations

Soon will be listed here.

Abstract

Purpose: To define the role of focal laser ablation (FLA) as clinical treatment of prostate cancer (PCa) using the Delphi consensus method.

Methods: A panel of international experts in the field of focal therapy (FT) in PCa conducted a collaborative consensus project using the Delphi method. Experts were invited to online questionnaires focusing on patient selection and treatment of PCa with FLA during four subsequent rounds. After each round, outcomes were displayed, and questionnaires were modified based on the comments provided by panelists. Results were finalized and discussed during face-to-face meetings.

Results: Thirty-seven experts agreed to participate, and consensus was achieved on 39/43 topics. Clinically significant PCa (csPCa) was defined as any volume Grade Group 2 [Gleason score (GS) 3+4]. Focal therapy was specified as treatment of all csPCa and can be considered primary treatment as an alternative to radical treatment in carefully selected patients. In patients with intermediate-risk PCa (GS 3+4) as well as patients with MRI-visible and biopsy-confirmed local recurrence, FLA is optimal for targeted ablation of a specific magnetic resonance imaging (MRI)-visible focus. However, FLA should not be applied to candidates for active surveillance and close follow-up is required. Suitability for FLA is based on tumor volume, location to vital structures, GS, MRI-visibility, and biopsy confirmation.

Conclusion: Focal laser ablation is a promising technique for treatment of clinically localized PCa and should ideally be performed within approved clinical trials. So far, only few studies have reported on FLA and further validation with longer follow-up is mandatory before widespread clinical implementation is justified.

Citing Articles

Focal therapy of prostate cancer: Use of artificial intelligence to define tumour volume and predict treatment outcomes.

Brisbane W, Priester A, Nguyen A, Topoozian M, Mota S, Delfin M BJUI Compass. 2025; 6(1):e456.

PMID: 39877558 PMC: 11771490. DOI: 10.1002/bco2.456.

High-Intensity Focused Ultrasound Ablation for Primary or Salvage Prostate Cancer Therapy: Initial Outcomes in the Veteran Healthcare Setting.

Patel S, Antar A, Alrabaa A, Saffati G, Fleming B, Srikishen N Life (Basel). 2025; 15(1).

PMID: 39859958 PMC: 11766662. DOI: 10.3390/life15010017.

Quantitative investigations on light emission profiles for interstitial laser treatment.

Ta M, Kim Y, Shin H, Truong V, Kang H Biomed Opt Express. 2024; 15(12):6877-6892.

PMID: 39679393 PMC: 11640558. DOI: 10.1364/BOE.540470.

Identifying the best candidate for focal therapy: a comprehensive review.

Ghoreifi A, Gomella L, Hu J, Konety B, Lunelli L, Rastinehad A Prostate Cancer Prostatic Dis. 2024; .

PMID: 39443815 DOI: 10.1038/s41391-024-00907-y.

Surveillance after Focal Therapy - a Comprehensive Review.

Marra G, Marquis A, Suberville M, Woo H, Govorov A, Hernandez-Porras A Prostate Cancer Prostatic Dis. 2024; .

PMID: 39367182 DOI: 10.1038/s41391-024-00905-0.

References

Postema A, de Reijke T, Ukimura O, van den Bos W, Azzouzi A, Barret E . Standardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project. World J Urol. 2016; 34(10):1373-82. PMC: 5026990. DOI: 10.1007/s00345-016-1782-x. View

Scheltema M, Chang J, Bohm M, van den Bos W, Blazevski A, Gielchinsky I . Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy. World J Urol. 2018; 36(9):1383-1389. PMC: 6105143. DOI: 10.1007/s00345-018-2281-z. View

Lepor H, Llukani E, Sperling D, Futterer J . Complications, Recovery, and Early Functional Outcomes and Oncologic Control Following In-bore Focal Laser Ablation of Prostate Cancer. Eur Urol. 2015; 68(6):924-6. DOI: 10.1016/j.eururo.2015.04.029. View

Valerio M, Ahmed H, Emberton M, Lawrentschuk N, Lazzeri M, Montironi R . The role of focal therapy in the management of localised prostate cancer: a systematic review. Eur Urol. 2013; 66(4):732-51. PMC: 4179888. DOI: 10.1016/j.eururo.2013.05.048. View

Faure Walker N, Norris J, Shah T, Yap T, Cathcart P, Moore C . A comparison of time taken to return to baseline erectile function following focal and whole gland ablative therapies for localized prostate cancer: A systematic review. Urol Oncol. 2017; 36(2):67-76. DOI: 10.1016/j.urolonc.2017.12.002. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

Eggener S, Salomon G, Scardino P, de la Rosette J, Polascik T, Brewster S . Focal therapy for prostate cancer: possibilities and limitations. Eur Urol. 2010; 58(1):57-64. DOI: 10.1016/j.eururo.2010.03.034. View

Resnick M, Koyama T, Fan K, Albertsen P, Goodman M, Hamilton A . Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013; 368(5):436-45. PMC: 3742365. DOI: 10.1056/NEJMoa1209978. View

Felker E, Lee-Felker S, Feller J, Margolis D, Lu D, Princenthal R . In-bore magnetic resonance-guided transrectal biopsy for the detection of clinically significant prostate cancer. Abdom Radiol (NY). 2016; 41(5):954-62. DOI: 10.1007/s00261-016-0750-7. View

10.

Lindner U, Weersink R, Haider M, Gertner M, Davidson S, Atri M . Image guided photothermal focal therapy for localized prostate cancer: phase I trial. J Urol. 2009; 182(4):1371-7. DOI: 10.1016/j.juro.2009.06.035. View

11.

Lindner U, Lawrentschuk N, Weersink R, Davidson S, Raz O, Hlasny E . Focal laser ablation for prostate cancer followed by radical prostatectomy: validation of focal therapy and imaging accuracy. Eur Urol. 2010; 57(6):1111-4. DOI: 10.1016/j.eururo.2010.03.008. View

12.

Natarajan S, Jones T, Priester A, Geoghegan R, Lieu P, Delfin M . Focal Laser Ablation of Prostate Cancer: Feasibility of Magnetic Resonance Imaging-Ultrasound Fusion for Guidance. J Urol. 2017; 198(4):839-847. DOI: 10.1016/j.juro.2017.04.017. View

13.

de la Rosette J, Ahmed H, Barentsz J, Johansen T, Brausi M, Emberton M . Focal therapy in prostate cancer-report from a consensus panel. J Endourol. 2010; 24(5):775-80. DOI: 10.1089/end.2009.0596. View

14.

Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S . Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2014; 33(3):272-7. DOI: 10.1200/JCO.2014.55.1192. View

15.

Yaxley A, Yaxley J, Thangasamy I, Ballard E, Pokorny M . Comparison between target magnetic resonance imaging (MRI) in-gantry and cognitively directed transperineal or transrectal-guided prostate biopsies for Prostate Imaging-Reporting and Data System (PI-RADS) 3-5 MRI lesions. BJU Int. 2017; 120 Suppl 3:43-50. DOI: 10.1111/bju.13971. View

16.

Ahmed H, Hindley R, Dickinson L, Freeman A, Kirkham A, Sahu M . Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol. 2012; 13(6):622-32. PMC: 3366323. DOI: 10.1016/S1470-2045(12)70121-3. View

17.

Oto A, Sethi I, Karczmar G, McNichols R, Ivancevic M, Stadler W . MR imaging-guided focal laser ablation for prostate cancer: phase I trial. Radiology. 2013; 267(3):932-40. DOI: 10.1148/radiol.13121652. View

18.

Sfoungaristos S, Perimenis P . PSA density is superior than PSA and Gleason score for adverse pathologic features prediction in patients with clinically localized prostate cancer. Can Urol Assoc J. 2012; 6(1):46-50. PMC: 3289697. DOI: 10.5489/cuaj.11079. View

19.

Tay K, Cheng C, Lau W, Khoo J, Thng C, Kwek J . Focal Therapy for Prostate Cancer with In-Bore MR-guided Focused Ultrasound: Two-Year Follow-up of a Phase I Trial-Complications and Functional Outcomes. Radiology. 2017; 285(2):620-628. DOI: 10.1148/radiol.2017161650. View

20.

Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch M, De Santis M . EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2016; 71(4):618-629. DOI: 10.1016/j.eururo.2016.08.003. View